Treatment of Advanced Stage Ovarian Cancer

  • John Butler
  • Alexandra Lawrence


The survival of women with advanced ovarian cancer has recently been improved with the use of aggressive surgical debulking, novel chemotherapy regimens including intraperitoneal chemotherapy and the use of targeted chemotherapeutic agents. Currently, women are surviving longer with advanced ovarian cancer and treatment aims to improve quality of life along with increasing survival.


Ovarian Cancer Intraperitoneal Chemotherapy Advanced Ovarian Cancer Mechanical Bowel Preparation Recurrent Ovarian Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–4.PubMedGoogle Scholar
  2. 2.
    Meigs J. Tumors of the female pelvic organs. New York: Macmillan; 1934.Google Scholar
  3. 3.
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.PubMedCrossRefGoogle Scholar
  4. 4.
    Vergote I, Tropé CGC, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):269–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer. 1994;70(2):363–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47(2):203–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;8, CD007565.PubMedGoogle Scholar
  9. 9.
    Qiu L, Yang T, Shan X-H, Hu M-B, Li Y. Metastatic factors for Krukenberg tumor: a clinical study on 102 cases. Med Oncol. 2011;28(4):1514–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90(2):390–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974–9; discussion 979–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89(7):1532–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Ferrandina G, Sallustio G, Fagotti A, et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer. 2009;101(7):1066–73.PubMedCrossRefGoogle Scholar
  14. 14.
    Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(4):384–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Güenaga KF, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev (Online). 2011;(9):CD001544.Google Scholar
  17. 17.
    Tamussino KF, Lim PC, Webb MJ, Lee RA, Lesnick TG. Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol. 2001;80(1):79–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Fanning J, Valea FA. Perioperative bowel management for gynecologic surgery. Am J Obstet Gynecol. 2011;205(4):309–14.PubMedCrossRefGoogle Scholar
  19. 19.
    Wilmore DW, Kehlet H. Management of patients in fast track surgery. BMJ. 2001;322(7284):473–6 (Clinical research ed.).PubMedCrossRefGoogle Scholar
  20. 20.
    Lv D, Wang X, Shi G. Perioperative enhanced recovery programmes for gynaecological cancer patients. Cochrane Database Syst Rev. 2010;6, CD008239.PubMedGoogle Scholar
  21. 21.
    Eberhart LHJ, Koch T, Ploger B, et al. Enhanced recovery after major gynaecological surgery for ovarian cancer - an objective and patient-based assessment of a traditional versus a multimodal “fast track” rehabilitation programme. [German] Beschleunigte erholung nach laparotomien bei ovarialka. Anasthesiologie Intensivmedizin. 2008;49(4):180–94.Google Scholar
  22. 22.
    Gerardi MA, Santillan A, Meisner B, et al. A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers. Gynecol Oncol. 2008;108(2):282–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Armstrong DKD, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. doi: 10.1056/NEJMoa052985.Google Scholar
  24. 24.
    Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006;24(6):988–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.PubMedCrossRefGoogle Scholar
  27. 27.
    Rose PG, Nerenstone S, Brady MF, et al. Gynecologic Oncology Group. N Engl J Med. 2004;351(24):2489–97.PubMedCrossRefGoogle Scholar
  28. 28.
    Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13(8):1156–61.PubMedCrossRefGoogle Scholar
  29. 29.
    Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71(3):431–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Angioli R, Palaia I, Zullo MA, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006;100(3):455–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Krivak TC, Elkas JC, Rose GS, et al. The utility of hand-assisted laparoscopy in ovarian cancer. Gynecol Oncol. 2005;96(1):72–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Farghaly SA. Robotic-assisted laparoscopic anterior pelvic exenteration in patients with advanced ovarian cancer: Farghaly’s technique. Eur J Gynaecol Oncol. 2010;31(4):361–3.PubMedGoogle Scholar
  33. 33.
    von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol. 2003;90(3):619–24.CrossRefGoogle Scholar
  34. 34.
    Kolomainen DF, Daponte A, Barton DPJ, et al. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol. 2011;125(1):31–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Caceres A, Zhou Q, Iasonos A, et al. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol. 2008;108(3):482–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Harter P, Bois A, Hahmann M. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289–95.PubMedCrossRefGoogle Scholar
  38. 38.
    Son H, Khan SM, Rahaman J, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics. 2011;31(2):569–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Fagotti A, Fanfani F, Rossitto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology. 2008;75(3–4):152–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Holloway RW, Brudie LA, Rakowski JA, Ahmad S. Robotic-assisted resection of liver and diaphragm recurrent ovarian carcinoma: description of technique. Gynecol Oncol. 2011;120(3):419–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Henretta MS, Anderson CL, Angle JF, Duska LR. It’s not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters. Gynecol Oncol. 2011;123(2):342–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution’s experience. Gynecol Oncol. 2009;114(3):420–3.PubMedCrossRefGoogle Scholar
  43. 43.
    Yu J, Liang P, Yu X, Wang Y, Gao Y. Ultrasound-guided percutaneous microwave ablation of splenic metastasis: report of four cases and literature review. Int J Hyperthermia. 2011;27(5):517–22.PubMedCrossRefGoogle Scholar
  44. 44.
    Bristow RE, Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol. 2001;83(1):39–48.PubMedCrossRefGoogle Scholar
  45. 45.
    Jiao LR, Tierris I, Ayav A, et al. A new technique for spleen preservation with radiofrequency. Surgery. 2006;140(3):464–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–38.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Gynaecological OncologySt. Bartholomew’s HospitalLondonUK
  2. 2.Department of Gynaecological OncologySt. Bartholomew’s HospitalLondonUK
  3. 3.Queen’s HospitalRomfordUK

Personalised recommendations